MetaCap

Indaptus Therapeutics (INDP) vs Relmada Therapeutics (RLMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.

Summary

Relmada Therapeutics is the larger company by market cap ($346.7 million vs $301.1 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Head-to-head

INDP versus RLMD key metrics
MetricINDPRLMD
Share price$2.26$3.25
Market cap$301.13M$346.68M
1-day change-12.74%-0.91%
YTD return—-32.71%
1-year return—+63.32%
5-year return—-86.25%
EPS (TTM)$-6.15$-0.91
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$5.96$8.00
52-week low$0.92$1.80
Distance from 52-week high-62.08%-59.38%
Average volume822.38K1.34M
Shares outstanding133.24M106.67M
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

INDP vs RLMD FAQ

Which is bigger, Indaptus Therapeutics or Relmada Therapeutics?

Relmada Therapeutics (RLMD) is larger, with a market capitalization of $346.68M compared with $301.13M for Indaptus Therapeutics (INDP).

Are Indaptus Therapeutics and Relmada Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons